Glycopeptide Antibiotics Market to Reach $5.38 Billion by 2029 at 9.2% CAGR

 Aimed at strategic decision-makers, this report explores current opportunities, emerging trends, and market dynamics shaping the glycopeptide antibiotics sector.

What Is The Projected Market Size & Growth Rate Of The Glycopeptide Antibiotics Market?
The glycopeptide antibiotics market size has grown strongly in recent years. It will grow from $3.54 billion in 2024 to $3.78 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to increasing antibiotic resistance, rising incidence of infectious diseases, government initiatives, increasing healthcare expenditure, globalization of infectious diseases.

The glycopeptide antibiotics market size is expected to see strong growth in the next few years. It will grow to $5.38 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to emerging infectious diseases, increasing geriatric population, continued antibiotic resistance challenges, R&D investments and innovations, expansion of healthcare infrastructure. Major trends in the forecast period include increasing antibiotic resistance, advancements in research and development, global health emergencies driving demand, collaborations for antibiotic stewardship, market expansion in emerging economies.

Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9444&type=smp

What Is The Crucial Factor Driving The Global Glycopeptide Antibiotics Market?
The rising number of cancer and infectious disease cases is expected to propel the growth of the glycopeptide antibiotics market going forward. Cancer refers to a disease that occurs when certain body cells multiply beyond their limits and spread to other body regions, whereas, infectious diseases are disorders produced by organisms such as bacteria, viruses, fungus, or parasites. The glycopeptide antibiotics are used to treat a variety of infectious disorders caused by methicillin-resistant staphylococcus aureus, streptococcus, or enterococcus bacteria that are resistant to beta-lactams and other antibiotics. In cancer patients, glycopeptide antibiotics are used to boost radiotherapy's antitumor effects by eliminating not only the targeted cancer cells but also distant cancer cells farther in the body. For instance, according to the American Cancer Society, a US-based non-profit health organization committed to cancer eradication, in 2022, the US had 1.9 million new cancer cases and 609,360 cancer deaths, for a total of 1,670 fatalities each day. Therefore, the rising cancer and infectious disease cases will drive the growth of the glycopeptide antibiotics market.

Segment Covered In The Glycopeptide Antibiotics Market Report
The glycopeptide antibiotics market covered in this report is segmented –

1) By Drug: Vancomycin, Dalbavancin, Oritavancin, Other Drugs
2) By Route of Administration: Oral, Parenteral, Other Routes
3) By Indication: Skin And Structure Infection, Meningitis, Clostridioides Difficile Infection, Enterocolitis, Other Indications
4) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:
1) By Vancomycin: Vancomycin Injection, Vancomycin Oral Solution, Vancomycin Capsules, Vancomycin Powder for Solution
2) By Dalbavancin: Dalbavancin IV (Intravenous) Formulation, Dalbavancin Powder for Injection
3) By Oritavancin: Oritavancin IV (Intravenous) Formulation,Oritavancin Powder for Injection
4) By Other Drugs: Teicoplanin, Linezolid, Daptomycin, Other Glycopeptide and Lipoglycopeptide Antibiotics





4o

Key Trends Driving Growth In The Glycopeptide Antibiotics Market
Product innovation is a key trend gaining popularity in the glycopeptide antibiotics market. Major companies operating in the glycopeptide antibiotics market are focused on developing innovative products to strengthen their position in the market. For instance, In October 2022, Leiden University, a Netherlands-based research university, discovered new variants of the antibiotic vancomycin. A group of molecules was attached to the structure of an existing vancomycin molecule to create the new variant antibiotic vancomycin. The new variant of vancomycin is up to a thousand times more active against gram-positive bacteria than the original vancomycin and has lower nephrotoxicity when compared to commercially utilized polymyxin antibiotics. This was created to solve the problem since vancomycin can only be effective against gram-positive strains and it cannot pass through the outer membrane (OM) of gram-negative bacteria.

Key Player In The Glycopeptide Antibiotics Market
Major companies operating in the glycopeptide antibiotics market include ANI Pharmaceuticals Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Novartis AG, Hikma Pharmaceuticals Plc., Aurobindo Pharma Limited, Abbvie Inc., Cumberland Pharmaceuticals Inc., Janssen Global, Bristol-Myers Squibb Company, Shenwei Pharmaceutical Hainan Co. Ltd., Zhejiang Hisun Pharmaceutical Co. Ltd., Alvogen, Bayer AG, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., Sanofi SA, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca, Boehringer Ingelheim GmbH, Cipla Inc.

View the full glycopeptide antibiotics market report here:
Glycopeptide Antibiotics Market 2025

Global Glycopeptide Antibiotics Market - Regional Insights:
North America was the largest region in the glycopeptide antibiotics market in 2024. The regions covered in the glycopeptide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

#Contact Us:#

The Business Research Company

Market Research Reports

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


#Follow Us On:#

LinkedIn: The Business Research Company | LinkedIn